AI Article Synopsis
- Botulinum neurotoxin (BoNT) has been utilized since the 1970s, primarily by blocking acetylcholine release in motor neurons and associated areas to affect muscle movement.
- It is increasingly being used to treat various motor and non-motor symptoms of Parkinson's disease, sometimes becoming the preferred treatment for specific symptoms.
- The text aims to summarize the indications for BoNT use, its potential side effects, and the regulatory approvals for its therapies addressing both primary and secondary symptoms of Parkinson's disease.
Article Abstract
Botulinum neurotoxin (BoNT) has been in use since the 1970's. Its effect is reached mainly by inhibiting the release of acetylcholine in the synaptic gap of motor neurons or at the motor end plate and the parasympathetic ganglia. In the case of Parkinson's disease, it is used to treat several motor and non-motor symptoms. Within recent years increasingly numerous possible fields of application of BoNT have been found for the treatment of Parkinson's disease, and for some specific symptoms it has in fact become the therapy of choice, while for others it is but one of the therapeutic options that come into consideration when others are not sufficiently effective. In the following, we intend to outline the indications, the possible side effects and also the approvals for therapies with botulinum toxin in the primary and secondary symptoms of Parkinson's disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00702-024-02805-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!